Physician profile
Beth S Du
NPI 1639122245
$2,246.67
in general payments reported to CMS, 2019-2025
35 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $73.34 · 2021: $508 · 2022: $584 · 2023: $460 · 2024: $170 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $668.41 | 2021-2023 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $262.15 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $203.96 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $144.35 | 2021-2025 | |
| Abbott Laboratories | $108.66 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $106.63 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $92.05 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $74.51 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $44.17 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Otsuka America Pharmaceutical, INC. | $41.09 | 2022 | |
| Exact Sciences Corporation | $36.07 | 2023-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $35.44 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $30.91 | 2024-2025 | Uptravi, Opsumit |
| Biohaven Pharmaceuticals, INC. | $28.89 | 2021 | |
| Boston Scientific Corporation | $28.28 | 2025 | Watchman Access System |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.30 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.89 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.28 | 2025 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $21.40 | 2023 | Heplisav-B |
| Astellas Pharma US INC | $20.82 | 2020 | |
| Lundbeck LLC | $20.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.40 | 2023 | |
| Dexcom, INC. | $18.60 | 2023 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $18.26 | 2021 | |
| Edwards Lifesciences Corporation | $18.09 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Radius Health, INC. | $17.48 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.09 | 2022 | |
| Abiomed | $15.84 | 2024 | Impella |
| Amneal Pharmaceuticals LLC | $14.56 | 2025 | Unithroid |
| Almatica Pharma LLC | $13.30 | 2021 | |
| Esperion Therapeutics, INC. | $11.78 | 2022 | |
| Amarin Pharma, INC. | $11.73 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.